Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Accrued Liabilities

v3.24.2.u1
Note 8 - Accrued Liabilities
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

8.         Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

June 30, 2024

   

December 31, 2023

 

Clinical trial costs

  $ 903     $ 258  

Research and development services

    688       632  

Compensation

    473       766  

Professional services fees

    155       98  

Other

    10       23  

Total accrued liabilities

  $ 2,229     $ 1,777